Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.
Michael S. Poirier, insider at Qualigen Therapeutics

Michael S. Poirier Insider Information

Michael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer. Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry. From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina. EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry. From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System. This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide. From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems. Both IMx and later, AxSym, became the leaders in their respective markets. Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.

What is Michael S. Poirier's net worth?

The estimated net worth of Michael S. Poirier is at least $107,808.12 as of June 22nd, 2022. Mr. Poirier owns 199,202 shares of Qualigen Therapeutics stock worth more than $107,808 as of June 30th. This net worth evaluation does not reflect any other investments that Mr. Poirier may own. Additionally, Mr. Poirier receives a salary of $742,280.00 as CEO at Qualigen Therapeutics. Learn More about Michael S. Poirier's net worth.

How old is Michael S. Poirier?

Mr. Poirier is currently 66 years old. There are 5 older executives and no younger executives at Qualigen Therapeutics. Learn More on Michael S. Poirier's age.

What is Michael S. Poirier's salary?

As the CEO of Qualigen Therapeutics, Inc., Mr. Poirier earned a total compensation package of $4,679,131.00 in 2020. Mr. Poirier earned a salary of $363,796.00, a bonus of $251,000.00, options awards of $4,063,412.00, and other compensation of $923.00. Learn More on Michael S. Poirier's salary.

How do I contact Michael S. Poirier?

The corporate mailing address for Mr. Poirier and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (310) 203-1000 and via email at [email protected] Learn More on Michael S. Poirier's contact information.

Has Michael S. Poirier been buying or selling shares of Qualigen Therapeutics?

During the last quarter, Michael S. Poirier has bought $17,100.00 of Qualigen Therapeutics stock. As an example of a recent trade by , on Thursday, June 30th, 0 shares of BMO Capital Markets stock. Learn More on Michael S. Poirier's trading history.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO). Learn More on Qualigen Therapeutics' active insiders.

Are insiders buying or selling shares of Qualigen Therapeutics?

During the last year, Qualigen Therapeutics insiders bought shares 3 times. They purchased a total of 68,000 shares worth more than $45,540.00. The most recent insider tranaction occured on June, 22nd when CEO Michael S Poirier bought 30,000 shares worth more than $17,100.00. Insiders at Qualigen Therapeutics own 4.7 % of the company. Learn More about insider trades at Qualigen Therapeutics.

Information on this page was last updated on 6/22/2022.

Michael S. Poirier Insider Trading History at Qualigen Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2022Buy30,000$0.57$17,100.00199,202View SEC Filing Icon  
4/20/2021Buy11,005$1.80$19,809.00169,202View SEC Filing Icon  
See Full Table

Michael S. Poirier Buying and Selling Activity at Qualigen Therapeutics

This chart shows Michael S Poirier's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Read More

Today's Range

Now: $0.54
Low: $0.54
High: $0.54

50 Day Range

MA: $0.56
Low: $0.45
High: $0.62

2 Week Range

Now: $0.54
Low: $0.45
High: $3.12


100 shs

Average Volume

801,628 shs

Market Capitalization

$21.00 million

P/E Ratio


Dividend Yield



A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
See Who Can Benefit From this Initiative